<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">At the current time, no extensive exploration of flavaglines toxicity has been disclosed. Yet, at doses where they exert potent cardioprotectant and anti-inflammatory effects, flavaglines did not exhibit any overt sign of toxicity [
 <xref rid="bib2" ref-type="bibr">2</xref>,
 <xref rid="bib5" ref-type="bibr">5</xref>]. In addition a synthetic flavagline developed by the eFFECTOR Therapeutics company, Zotatifin (also called eFT226, 
 <bold>4</bold>, 
 <xref rid="fig1" ref-type="fig">Fig.Â 1</xref>) has passed the US regulatory toxicology requirements necessary to enter a phase 1/2 clinical trial against advanced solid tumors refractory or intolerant to standard treatments [
 <xref rid="bib19" ref-type="bibr">19</xref>,
 <xref rid="bib20" ref-type="bibr">20</xref>]. While it was shown to inhibit eIF4A, its putative effect on PHB signaling has not yet been disclosed.
</p>
